Safety run-in and part 1 of GIMEMA AML1718: venetoclax combined with FLAI as induction treatment in non–low-risk AML

Safety run-in and part 1 of GIMEMA AML1718: venetoclax combined with FLAI as induction treatment in non–low-risk AML

Abstract: The standard induction treatment for acute myeloid leukemia (AML) has limited efficacy for patients with non–low-risk AML. We conducted a multicenter study phase 1b/2, Gruppo Italiano Malattie EMatologiche dell'Adulto AML1718, to investigate the safety and efficacy of venetoclax (VEN)...

Full description

Saved in:
Bibliographic Details
Main Authors: Giovanni Marconi, Alfonso Piciocchi, Ernesta Audisio, Cristina Papayannidis, Marco Cerrano, Clara Minotti, Francesca Paoloni, Fabio Guolo, Monica Bocchia, Michela Rondoni, Albana Lico, Matteo G. Carrabba, Matteo Giovanni Della Porta, Marco Frigeni, Luisa Giaccone, Germana Beltrami, Chiara Cattaneo, Maria Chiara Di Chio, Bianca Serio, Enrico Crea, Roberto Freilone, Saveria Capria, Antonio Curti, Paola Minetto, Edoardo la Sala, Jacopo Nanni, Beatrice Anna Zannetti, Giorgia Simonetti, Maria Teresa Bochicchio, Giuseppe Saglio, Roberto M. Lemoli, Adriano Venditti, Marco Vignetti, Paola Fazi, Giovanni Martinelli
Format: Article
Language:English
Published: Elsevier 2025-05-01
Series:Blood Advances
Online Access:http://www.sciencedirect.com/science/article/pii/S2473952925001521
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

http://www.sciencedirect.com/science/article/pii/S2473952925001521

Similar Items